BB BIOTECH’s objective is to generate an average return of 15% per annum with a long-term investment horizon and to substantially outperform the relevant indices in the process.

BB BIOTECH participates selectively in firms operating in the growth market of innovative medications and diagnostics based on modern biotechnology, with companies listed in the stock markets accounting for at least 90% of the portfolio value. Selective investments are also made in emerging markets.

Our task is to have an in-depth knowledge of business conducted by our holdings, i.e. in addition to purely key financial ratios, also of the prevailing competitive environment, the innovation pipeline, the portfolio of patents and the perception of products and services by end customers, to name but a few further aspects.

The target portfolio of BB BIOTECH  consists generally of approx. 20 to 30 holdings, no more than 5 of which account for more than 10% of equity and the largest of which should not exceed 25%. In the process, we deliberately decline to choose a portfolio structure of statistical relevance as we attach importance to the depth of sector and company expertise and seek personal access to the management of our equity interests.